PHOENIX,, Jan. 12, 2012 /PRNewswire/ -- Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery system is pleased to announce that has initiated the development of Gleevec®. Gleevec® is an important anti-cancer drug for the treatment of several blood related cancers in children and adults. In children the drug has demonstrated a powerful action against Chronic Myeloid Leukemia, possibly one of the most prescribed drugs for this condition. The drug is administered orally and in children there is a significant issue in getting the drug swallowed, due to size of the pill and bad taste. Our sublingual formulation with taste masking features makes the drug acceptable and pleasant in taste for the children with chronic dosage requirements.
Gleevec® is the registered trade name for Imatinib, a specific inhibitor of tyrosine kinase BCR-ABL. BCR-ABL is a fusion protein created by the Philadelphia Chromosome abnormality that characterizes chronic myeloid leukemia (CML). Prior to discovery of Gleevec®, the disease (CML) treatment was very unsuccessful. However, with the discovery of Gleevec®, the treatment of CML has been tremendously successful. The oral prescription dose of Gleevec®, is marketed by Novartis Pharmaceuticals.
About Kedem Pharmaceuticals Inc. KDMP.OB
A specialty pharmaceutical company with expertise in drug delivery and formulation. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. The Company has several other drugs under development for fast and convenient delivery. These include drugs for osteoporosis, sleeping disorders, pain killers, migraine, anti-allergy medications, cardiovascular diseases, lung medications, and addiction replacement therapies. For more information visit www.kedempharmaceuticals.com
This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Additionally this press release include statement within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to high risks, uncertainties and other factors, including that the Regulatory Agencies may not agree to the claims made in the Company documents related to our products, and product development. There are risks that due to un foreseen reasons, matters could cause the actual results to differ materially from those referred in our fillings. Risks involved patent infringement, trademark and other commercially related actions that hinder the product development and marketing. Additional risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission, as well as to obtain independent third party opinions before investing in the Company's securities.
For further information, contact:
Kedem Investor Relations 1 866 465-6551
Mrs. Kelly Black
Premier Media Services 1 480 649 8224
SOURCE Kedem Pharmaceuticals Inc.